APTOF · As filed with the SEC
Aptose Biosciences balance sheet, by quarter
The statement as Aptose Biosciences presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Condensed Consolidated Interim Statements of Financial Position (Current Period Unaudited) · USD
| USD | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 | Q2 2025 Jun 30, 2025 |
|---|---|---|---|---|
| Current assets: | ||||
| Cash and cash equivalents | — | 935,000 | 613,000 | 553,000 |
| Restricted cash equivalents, current | — | — | — | 745,000 |
| Restricted cash and restricted cash equivalents | — | 3,161,000 | 1,024,000 | — |
| Cash | 1,020,000 | — | — | — |
| Restricted cash | 3,085,000 | — | — | — |
| Prepaid expenses | 1,845,000 | 2,209,000 | 2,013,000 | 1,857,000 |
| Other current assets | 205,000 | 141,000 | 127,000 | 116,000 |
| Total current assets | 6,155,000 | 6,446,000 | 3,777,000 | 3,271,000 |
| Non-current assets: | ||||
| Property and equipment, net | 2,000 | 4,000 | 8,000 | 19,000 |
| Right-of-use assets, operating leases | 71,000 | 175,000 | 277,000 | 377,000 |
| Other long-term assets | 4,495,000 | 3,387,000 | 2,279,000 | 1,924,000 |
| Total non-current assets | 4,568,000 | 3,566,000 | 2,564,000 | 2,320,000 |
| Total assets | 10,723,000 | 10,012,000 | 6,341,000 | 5,591,000 |
| Current liabilities: | ||||
| Accounts payable | 3,810,000 | 2,911,000 | 1,456,000 | 2,879,000 |
| Accrued liabilities | 7,349,000 | 6,202,000 | 4,804,000 | 5,414,000 |
| Current portion of lease liability, operating leases | 80,000 | 193,000 | 305,000 | 413,000 |
| Interest on related party loan payable | — | — | 514,000 | 294,000 |
| Total current liabilities | 11,239,000 | 9,306,000 | 7,079,000 | 9,000,000 |
| Non-current liabilities: | ||||
| Lease liability, operating leases | — | 0 | 0 | 0 |
| Loan payable to related party | 32,870,000 | 27,018,000 | 18,712,000 | 10,962,000 |
| Interest on related party loan payable | 1,286,000 | 855,000 | — | — |
| Total non-current liabilities | 34,156,000 | 27,873,000 | 18,712,000 | 10,962,000 |
| Total liabilities | 45,395,000 | 37,179,000 | 25,791,000 | 19,962,000 |
| Shareholders' deficit: | ||||
| Common shares, no par value, unlimited authorized shares, 2,552,429 issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 459,771,000 | 459,771,000 | 459,771,000 | 459,771,000 |
| Additional paid-in capital | 83,942,000 | 83,813,000 | 83,771,000 | 83,727,000 |
| Accumulated other comprehensive loss | (4,316,000) | (4,316,000) | (4,316,000) | (4,316,000) |
| Accumulated deficit | (574,069,000) | (566,435,000) | (558,676,000) | (553,553,000) |
| Total shareholders' deficit | (34,672,000) | (27,167,000) | (19,450,000) | (14,371,000) |
| Total liabilities and shareholders' deficit | 10,723,000 | 10,012,000 | 6,341,000 | 5,591,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.